17:43 , Oct 24, 2018 |  BC Week In Review  |  Company News

Anaeropharma and Chugai partner to discover cancer drugs using anaerobic bacteria

Anaeropharma Science Inc. (Tokyo, Japan) and Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) partnered to conduct joint research to discover cancer treatments using Anaeropharma's...
23:20 , Mar 1, 2018 |  BC Innovations  |  Targets & Mechanisms

Checking out the microbiome

What started out as a potential use in stratifying patients is growing into a new avenue for turning non-responders to responders, as evidence continues to emerge linking the microbiome to immuno-oncology. While the data are...
19:01 , Jul 5, 2017 |  BC Extra  |  Financial News

Microbiome company Anaeropharma raises $13.2M

Microbiome and cancer play Anaeropharma Science Inc. (Tokyo, Japan) raised $13.2 million from new investors Novartis AG (NYSE:NVS; SIX:NOVN), Shinsei Corporate Investment and Seventure Partners’ Health for Life Capital. Existing investors Innovation Network Corp. of...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

APS001F: Phase I/II started

Anaeropharma began a dose-escalation, U.S. Phase I/II trial to evaluate IV APS001F given on days 1-3 of a 28-day cycle in combination with oral 5-flucytosine in about 75 patients. Anaeropharma Science Inc. , Tokyo, Japan...